ZA200602677B - Pyrazolo and imidazo-pyrimidine derivatives - Google Patents

Pyrazolo and imidazo-pyrimidine derivatives Download PDF

Info

Publication number: ZA200602677B
Authority: ZA; South Africa
Prior art keywords: hydrogen; alkyl; unsubstituted; substituted; halogen
Prior art date: 2003-10-03

Application number

ZA200602677A

Other languages

English (en)

Inventor

Wichmann Juergen

Woltering Thomas Johannes

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-03

Filing date

2006-03-31

Publication date

2007-09-26

2006-03-31 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2007-09-26 Publication of ZA200602677B publication Critical patent/ZA200602677B/en

Links

OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
150000005237 imidazopyrimidines Chemical class 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 claims description 202
239000001257 hydrogen Substances 0.000 claims description 202
150000002431 hydrogen Chemical class 0.000 claims description 155
229910052731 fluorine Inorganic materials 0.000 claims description 102
229910052736 halogen Inorganic materials 0.000 claims description 99
150000002367 halogens Chemical class 0.000 claims description 99
239000011737 fluorine Substances 0.000 claims description 96
125000001153 fluoro group Chemical group F* 0.000 claims description 76
150000001875 compounds Chemical class 0.000 claims description 62
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
125000004076 pyridyl group Chemical group 0.000 claims description 28
125000001309 chloro group Chemical group Cl* 0.000 claims description 16
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
238000000034 method Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
235000019000 fluorine Nutrition 0.000 claims 48
229940060037 fluorine Drugs 0.000 claims 47
230000000875 corresponding effect Effects 0.000 claims 9
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
208000019901 Anxiety disease Diseases 0.000 claims 2
208000002193 Pain Diseases 0.000 claims 2
208000028017 Psychotic disease Diseases 0.000 claims 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
230000004913 activation Effects 0.000 claims 2
230000001154 acute effect Effects 0.000 claims 2
230000036506 anxiety Effects 0.000 claims 2
230000001149 cognitive effect Effects 0.000 claims 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
208000030507 AIDS Diseases 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
206010007559 Cardiac failure congestive Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
206010010904 Convulsion Diseases 0.000 claims 1
206010012289 Dementia Diseases 0.000 claims 1
206010012335 Dependence Diseases 0.000 claims 1
208000012661 Dyskinesia Diseases 0.000 claims 1
208000020564 Eye injury Diseases 0.000 claims 1
102000018899 Glutamate Receptors Human genes 0.000 claims 1
108010027915 Glutamate Receptors Proteins 0.000 claims 1
206010019196 Head injury Diseases 0.000 claims 1
208000010496 Heart Arrest Diseases 0.000 claims 1
208000023105 Huntington disease Diseases 0.000 claims 1
208000013016 Hypoglycemia Diseases 0.000 claims 1
206010021143 Hypoxia Diseases 0.000 claims 1
208000026139 Memory disease Diseases 0.000 claims 1
102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
208000007101 Muscle Cramp Diseases 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
240000007594 Oryza sativa Species 0.000 claims 1
208000027089 Parkinsonian disease Diseases 0.000 claims 1
206010034010 Parkinsonism Diseases 0.000 claims 1
208000017442 Retinal disease Diseases 0.000 claims 1
206010038923 Retinopathy Diseases 0.000 claims 1
208000005392 Spasm Diseases 0.000 claims 1
206010046543 Urinary incontinence Diseases 0.000 claims 1
201000004810 Vascular dementia Diseases 0.000 claims 1
206010047700 Vomiting Diseases 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
230000007000 age related cognitive decline Effects 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
230000036770 blood supply Effects 0.000 claims 1
210000004556 brain Anatomy 0.000 claims 1
208000029028 brain injury Diseases 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
230000036461 convulsion Effects 0.000 claims 1
230000006378 damage Effects 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
230000006870 function Effects 0.000 claims 1
230000007954 hypoxia Effects 0.000 claims 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
201000010901 lateral sclerosis Diseases 0.000 claims 1
206010027175 memory impairment Diseases 0.000 claims 1
239000003512 metabotropic receptor antagonist Substances 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
208000005264 motor neuron disease Diseases 0.000 claims 1
229960002715 nicotine Drugs 0.000 claims 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
229940127240 opiate Drugs 0.000 claims 1
230000035935 pregnancy Effects 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
201000000980 schizophrenia Diseases 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
230000008673 vomiting Effects 0.000 claims 1
235000013350 formula milk Nutrition 0.000 description 25
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 16
-1 —yclobutyl Chemical group 0.000 description 9
239000000460 chlorine Substances 0.000 description 5
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001721 carbon Chemical class 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000001436 propyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Virology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200602677A 2003-10-03 2006-03-31 Pyrazolo and imidazo-pyrimidine derivatives ZA200602677B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03078075		2003-10-03

Publications (1)

Publication Number	Publication Date
ZA200602677B true ZA200602677B (en)	2007-09-26

Family

ID=34486287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200602677A ZA200602677B (en)	2003-10-03	2006-03-31	Pyrazolo and imidazo-pyrimidine derivatives

Country Status (21)

Country	Link
US (2)	US7329662B2 (de)
EP (1)	EP1670801B1 (de)
JP (1)	JP4551402B2 (de)
KR (2)	KR20070096033A (de)
CN (2)	CN100522964C (de)
AR (1)	AR045959A1 (de)
AT (1)	ATE512148T1 (de)
AU (1)	AU2004283801B2 (de)
BR (1)	BRPI0414948A (de)
CA (1)	CA2540768C (de)
CO (1)	CO5680437A2 (de)
ES (1)	ES2364753T3 (de)
HK (1)	HK1099302A1 (de)
IL (1)	IL174512A0 (de)
MX (1)	MXPA06003526A (de)
NO (1)	NO20061363L (de)
NZ (1)	NZ546037A (de)
RU (1)	RU2350616C2 (de)
TW (1)	TWI297691B (de)
WO (1)	WO2005040171A1 (de)
ZA (1)	ZA200602677B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7329662B2 (en) *	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine
PT1761541E (pt) *	2004-06-21	2008-03-13	Hoffmann La Roche	Derivados de pirazole-pirimidina
CN101115755B (zh) *	2005-02-11	2013-01-16	弗·哈夫曼-拉罗切有限公司	作为mglur2拮抗剂的吡唑并-嘧啶衍生物
ATE460417T1 (de)	2005-03-23	2010-03-15	Hoffmann La Roche	Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
CA2623721C (en)	2005-09-27	2014-05-13	F. Hoffmann-La Roche Ag	Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
WO2009014620A1 (en) *	2007-07-20	2009-01-29	Merck & Co., Inc.	Pyrazolo[1,5-a]pyrimidine derivatives
CN101671336B (zh) *	2009-09-23	2013-11-13	辽宁利锋科技开发有限公司	芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US9447099B2 (en) *	2011-10-04	2016-09-20	Hoffmann-La Roche Inc.	Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
EP2882712A2 (de) *	2012-07-27	2015-06-17	BIAL - Portela & Cª S.A.	Verfahren zur synthese von substituierten harnstoffverbindungen
WO2014064028A1 (en)	2012-10-23	2014-05-01	F. Hoffmann-La Roche Ag	Mglu2/3 antagonists for the treatment of autistic disorders
MY182036A (en)	2013-02-21	2021-01-18	Sunshine Lake Pharma Co Ltd	Heteroaromatic compounds as pi3 kinase modulators
TW201542550A (zh) *	2013-09-06	2015-11-16	Lexicon Pharmaceuticals Inc	吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
CN104193745B (zh) *	2014-07-30	2016-09-28	斯芬克司药物研发（天津）股份有限公司	一种咪唑并嘧啶羧酸类化合物及其制备方法
JP6517340B2 (ja) *	2014-08-01	2019-05-22	ヤンセンファーマシューティカエヌ．ベー．	６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
EP3000814A1 (de)	2014-09-26	2016-03-30	Domain Therapeutics	Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
EP3226915B1 (de)	2014-12-03	2019-02-20	Janssen Pharmaceutica NV	Radioaktiv markierte mglur2-pet-liganden
TWI713497B (zh) *	2015-02-26	2020-12-21	南韓商愛思開生物製藥股份有限公司	咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
AU2016311426B2 (en)	2015-08-26	2021-05-20	Blueprint Medicines Corporation	Compounds and compositions useful for treating disorders related to NTRK
EP3377497A1 (de)	2015-11-19	2018-09-26	Blueprint Medicines Corporation	Verbindungen und zusammensetzungen zur behandlung von störungen im zusammenhang mit ntrk
EP3389728B1 (de)	2015-12-18	2020-08-05	Janssen Pharmaceutica NV	Radioaktiv markierte mglur2/3 pet-liganden
EP3389727B1 (de)	2015-12-18	2020-08-12	Janssen Pharmaceutica NV	Radioaktiv markierte mglur2/3 pet-liganden
US11649238B2 (en) *	2018-01-17	2023-05-16	Glaxosmithkline Intellectual Property Development Limited	Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04282B1 (et)	1996-02-07	2004-04-15	Janssen Pharmaceutica N.V.	Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon
JP4704521B2 (ja) *	1996-07-24	2011-06-15	ブリストル−マイヤーズスクイブファーマカンパニー	アゾロトリアジン類およびアゾロピリミジン類
PT891978E (pt) *	1997-07-18	2002-07-31	Hoffmann La Roche	Derivados de 5h-tiazolo (3,2-a) pirimidina
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
EP1379511B1 (de)	2001-04-12	2005-07-20	F. Hoffmann-La Roche Ag	DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
GB0128499D0 (en)	2001-11-28	2002-01-23	Merck Sharp & Dohme	Therapeutic agents
EP1453815A4 (de) *	2001-11-30	2005-04-06	Merck & Co Inc	Modulatoren des metabotropen glutamatrezeptors-5
US7329662B2 (en) *	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine

2004
- 2004-09-24 US US10/948,970 patent/US7329662B2/en not_active Expired - Fee Related
- 2004-09-27 KR KR1020077018904A patent/KR20070096033A/ko not_active Application Discontinuation
- 2004-09-27 MX MXPA06003526A patent/MXPA06003526A/es active IP Right Grant
- 2004-09-27 EP EP04765633A patent/EP1670801B1/de not_active Expired - Lifetime
- 2004-09-27 JP JP2006530027A patent/JP4551402B2/ja not_active Expired - Fee Related
- 2004-09-27 RU RU2006114749/04A patent/RU2350616C2/ru not_active IP Right Cessation
- 2004-09-27 BR BRPI0414948-3A patent/BRPI0414948A/pt not_active IP Right Cessation
- 2004-09-27 NZ NZ546037A patent/NZ546037A/en unknown
- 2004-09-27 KR KR1020067006303A patent/KR100781469B1/ko not_active IP Right Cessation
- 2004-09-27 AU AU2004283801A patent/AU2004283801B2/en not_active Ceased
- 2004-09-27 WO PCT/EP2004/010807 patent/WO2005040171A1/en active Application Filing
- 2004-09-27 CN CNB2004800357899A patent/CN100522964C/zh not_active Expired - Fee Related
- 2004-09-27 AT AT04765633T patent/ATE512148T1/de active
- 2004-09-27 ES ES04765633T patent/ES2364753T3/es not_active Expired - Lifetime
- 2004-09-27 CN CN2008100836319A patent/CN101239981B/zh not_active Expired - Fee Related
- 2004-09-27 CA CA2540768A patent/CA2540768C/en not_active Expired - Fee Related
- 2004-09-30 TW TW093129636A patent/TWI297691B/zh active
- 2004-10-01 AR ARP040103565A patent/AR045959A1/es unknown
2006
- 2006-03-23 IL IL174512A patent/IL174512A0/en not_active IP Right Cessation
- 2006-03-24 NO NO20061363A patent/NO20061363L/no not_active Application Discontinuation
- 2006-03-31 ZA ZA200602677A patent/ZA200602677B/en unknown
- 2006-04-03 CO CO06032493A patent/CO5680437A2/es not_active Application Discontinuation
2007
- 2007-02-16 US US11/707,480 patent/US7514443B2/en not_active Expired - Fee Related
- 2007-06-18 HK HK07106520.9A patent/HK1099302A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1099302A1 (en)	2007-08-10
WO2005040171A1 (en)	2005-05-06
CO5680437A2 (es)	2006-09-29
AU2004283801A1 (en)	2005-05-06
ATE512148T1 (de)	2011-06-15
US7329662B2 (en)	2008-02-12
WO2005040171A8 (en)	2006-08-03
MXPA06003526A (es)	2006-06-08
RU2006114749A (ru)	2007-11-20
KR20060089731A (ko)	2006-08-09
JP4551402B2 (ja)	2010-09-29
NO20061363L (no)	2006-04-24
EP1670801B1 (de)	2011-06-08
BRPI0414948A (pt)	2006-11-07
TWI297691B (en)	2008-06-11
CA2540768A1 (en)	2005-05-06
JP2007507446A (ja)	2007-03-29
US20080051421A1 (en)	2008-02-28
CA2540768C (en)	2011-08-09
IL174512A0 (en)	2006-08-01
EP1670801A1 (de)	2006-06-21
AU2004283801B2 (en)	2010-04-22
RU2350616C2 (ru)	2009-03-27
CN101239981A (zh)	2008-08-13
US20050130992A1 (en)	2005-06-16
ES2364753T3 (es)	2011-09-13
KR100781469B1 (ko)	2007-12-03
US7514443B2 (en)	2009-04-07
NZ546037A (en)	2008-09-26
CN101239981B (zh)	2011-01-19
KR20070096033A (ko)	2007-10-01
CN100522964C (zh)	2009-08-05
TW200528453A (en)	2005-09-01
AR045959A1 (es)	2005-11-16
CN1890242A (zh)	2007-01-03

Publication	Publication Date	Title
ZA200602677B (en)	2007-09-26	Pyrazolo and imidazo-pyrimidine derivatives
MY140611A (en)	2009-12-31	Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CA2910507C (en)	2021-07-27	6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5.eta.)-one compounds and their use as negative allosteric modulators of mglur2 receptors
JP6446040B2 (ja)	2018-12-26	Ｋｉｔに関連する疾患を治療するために有用な組成物
AU2004262897B9 (en)	2009-12-17	Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
SG172805A1 (en)	2011-08-29	Amino-heterocyclic compounds used as pde9 inhibitors
WO2009006959A1 (de)	2009-01-15	Pyridazinonderivate
MXPA06007237A (es)	2006-08-18	Derivado de amida y medicamento que lo contiene.
EA200800508A1 (ru)	2008-06-30	Производные хинолина в качестве антибактериальных средств
HK1097474A1 (en)	2007-06-29	Carbostyril derivatives for accelerating salivation
CA2458929A1 (en)	2004-07-09	Process for preparing aripiprazole
MXPA04000407A (es)	2004-03-18	Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
KR20150058441A (ko)	2015-05-28	고형 종양의 치료 수단 및 방법
JP2006522769A5 (de)	2007-03-15
AU2004203910A8 (en)	2004-07-29	Use of 2-amino-2H-quinazoline derivatives for producing therapeutic agents
AU3431695A (en)	1996-05-02	Quinoxalines, a process for their preparation and their use
NO20072667L (no)	2007-09-06	Fremstillingsmetode
NZ324693A (en)	2000-01-28	2-(O-[pyrimidin-4-yl]methylenoxy)phenyl acetic acid derivatives and fungicidal composition
MY151030A (en)	2014-03-31	Quinoline derivatives as antibacterial agents
EP2371819A1 (de)	2011-10-05	Neue chinolinderivate, herstellungsverfahren und deren verwendung zur behandlung mikrobakterieller infektionen, und eine auf diesen derivaten basierende pharmazeutische zusammensetzung
EP3466948B1 (de)	2021-01-20	Kondensiertes pyrimidinpiperidinderivat sowie herstellungsverfahren und anwendung davon
CA2251927A1 (en)	1997-10-30	Cycloalkylaminomethylpyrrolidine derivatives
Van der Wilt et al.	1993	In vitro antitumour activity of cis-and trans-5-fluoro-5, 6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis
WO2022170164A1 (en)	2022-08-11	Sulfonamides with egfr inhibition activities and their use thereof
EP1419772A4 (de)	2004-11-24	Mittel zur prävention und behandlung des vorwiegend durch obstipation geprägten reizdarms